Åê¹Æµ¬Äê¤Ë¤Ä¤¤¤Æ

Åê¹Æµ¬Äê

ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ¡¡ (PDF¤Ï¤³¤Á¤é¡Ë
£±¡¥ÊÔ½¸Êý¿Ë

¡¡¡ÖÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ»¨»ï¡×¡ÊJournal of Hematopoietic Cell Transplantation¡Ë¡Ê°Ê²¼¡¢ËÜ»ï¤Èά¤¹¡£¡Ë¤Ï¡¢ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ¡Ê°Ê²¼¡¢Ëܳزñ¤Èά¤¹¡£¡Ë¤Îµ¡´Ø»ï¤È¤·¤Æ¡¢Â¤·ìºÙ˦°Ü¿¢¤Ë´Ø¤¹¤ë´ðÁÃŪ¡¦Î×¾²Åª¸¦µæ¤òȯɽ¤¹¤ë¡£ËÜ»ï¤ÎÏÀʸÆâÍÆ¤Ï¡¢¿·¤¿¤ÊÃθ«¤Ë´ð¤Å¤­¡¢Ëܳزñ°÷¤ª¤è¤ÓÆÉ¼Ô¤ËÍ­±×¤Ê¾ðÊó¤òÄ󶡤¹¤ë¤Èǧ¤á¤é¤ì¤¿¤â¤Î¤Ë¸Â¤ë¡£¤¹¤Ç¤Ë¾»ï¤Ëȯɽ¤µ¤ì¤¿¤â¤Î¡¢Åê¹ÆÃæ¤¢¤ë¤¤¤ÏÅê¹ÆÍ½Äê¤ÎÏÀʸ¤Ï¼õ¤±ÉÕ¤±¤Ê¤¤¡£

£²¡¥Åê¹Æ»ñ³Ê¡¦Åê¹ÆÊýË¡

Åê¹Æ»ñ³Ê¡§É¬¤º¤·¤âËܲñ²ñ°÷¤Ç¤¢¤ë¤³¤È¤ÏÌä¤ï¤Ê¤¤¡£
ÏÀʸ¤ÎÅê¹ÆÊýË¡¡§¡ÖÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ»¨»ï¡×¤Ï¥ª¥ó¥é¥¤¥óÅê¹Æ¥·¥¹¥Æ¥à¡ÊEditorialManager®¡Ë¤òºÎÍѤ·¤Æ¤¤¤ë¤Î¤Ç¡¢²¼µ­¥µ¥¤¥È¤è¤êÅê¹Æ¤¹¤ë¤³¤È¡£Åê¹Æ¸å¤ÎÏÀʸ¤Ë´Ø¤¹¤ë¾ðÊó¤ÏÅê¹Æ¥µ¥¤¥È¤Ë¥¢¥¯¥»¥¹¤¹¤ë¤³¤È¤Ç¡¤¤¤¤Ä¤Ç¤â³Îǧ¤Ç¤­¤ë¡£
¥ª¥ó¥é¥¤¥óÅê¹Æ¥µ¥¤¥È¡§https://www.editorialmanager.com/jshct/
½é²óÅê¹Æ¤Î¾ì¹ç¤Ï¥¢¥«¥¦¥ó¥È¤òºîÀ®¤¹¤ëɬÍפ¬¤¢¤ë¡£
¼¡¤Î¥¢¥¯¥»¥¹¤«¤é¤ÏÀßÄꤷ¤¿¥æ¡¼¥¶¡¼Ì¾¡¦¥Ñ¥¹¥ï¡¼¥É¤ò¥í¥°¥¤¥ó²èÌ̤Ρ֥桼¥¶¡¼Ì¾¡×¡Ö¥Ñ¥¹¥ï¡¼¥É¡×¤ÎÍó¤ËÆþÎϤ·¥í¥°¥¤¥ó¤¹¤ë¤³¤È¤¬¤Ç¤­¤ë¡£
Åê¹Æ¤Î½àÈ÷¤ËºÝ¤·¤Æ¤Ï¡¤¡ÖÃø¼Ô¡¦¥æ¡¼¥¶ÅÐÏ¿Íѥޥ˥奢¥ë¡×¡ÊÅê¹Æ¥µ¥¤¥È¤«¤é¥À¥¦¥ó¥í¡¼¥É¤Ç¤­¤ë¡Ë¤ò¤è¤¯ÆÉ¤ó¤Ç¤«¤éÍøÍѤ¹¤ë¤³¤È¡£¤Þ¤¿³Æ¥Ú¡¼¥¸¤Î»Ø¼¨¤Ë½¾¤Ã¤Æµ­ºÜ¤¹¤ë¤³¤È¡£
ÏÀʸ¤Ëµ­ºÜ¤¹¤Ù¤­Í×·ï¤Î°ìÉô¤Ï¡¢Åê¹Æ»þ¤Ë¡ÖÄɲÃÅê¹Æ¾ðÊó¡×¤Ø¤âµ­ºÜ¡Ê¥³¥Ô¡¼¡õ¥Ú¡¼¥¹¥È¤Ç²Ä¡Ë¤ò¤¹¤ë¤³¤È¡£
¡öµ­ºÜÉÔÈ÷¤¬¤¢¤ë¤ÈºÇ½ªÅê¹Æ¤Ø°Ü¤ì¤Þ¤»¤ó¤Î¤ÇÃí°Õ¤¹¤ë¤³¤È¡£


£³¡¥¼¹É®Í×¹à

£±¡Ë¸¶¹Æ¤Î¸À¸ì
¡¡ÆüËܸì¤Þ¤¿¤Ï±Ñ¸ì¤È¤¹¤ë¡£

£²¡Ë¸¶¹Æ¤Î¼ïÎà
¡¡ÁíÀâ¡¢¸¦µæÊó¹ð¡Ê´ðÁø¦µæ¤ª¤è¤ÓÎ×¾²¸¦µæ¡Ë¡¢¾ÉÎãÊó¹ð¡¢Ã»Êó¤Î4¼ïÎफ¤éÁªÂò¤¹¤ë¡£¤Ê¤ªÉ¬Íפ˱þ¤¸¤Æ¡¢ÊÔ½¸°Ñ°÷²ñ¤«¤éÁíÀ⡦²ó¸ÜÏ¿¤Ê¤É¤Î°ÍÍê¤ò¹Ô¤¦¤³¤È¤¬¤¢¤ë¡£¤Þ¤¿¡Ö»ä¤Î°ìËç¤Î²èÁü¡×¤Ç¤Ï¿ÇÃǤ˻ê¤ë¤­¤Ã¤«¤±¤È¤Ê¤Ã¤¿Åù¡¢Î×¾²¾å½ÅÍפʲèÁü¤òÊ罸¤¹¤ë¡£¤µ¤é¤Ë³Æ°Ü¿¢»ÜÀßÅù¤Î¤·ì´´ºÙ˦°Ü¿¢¤Ë´Ø¤¹¤ë³èưÊó¹ð¤ä¥¢¥ó¥±¡¼¥ÈÄ´ºº¤Ê¤É¤ÎÊó¹ð¤â¼õ¤±ÉÕ¤±¤ë¡£¤Ê¤ª¡¢¡Ö»ä¤Î°ìËç¤Î²èÁü¡×¤È³èưÊó¹ð¡¢²ó¸ÜÏ¿Åù¤Ï³Ø½ÑÏÀʸ¤È¤Ï°·¤ï¤ì¤Ê¤¤¤Î¤ÇÃí°Õ¤¹¤ë¤³¤È¡£

£³¡Ë¸¶¹ÆºîÀ®¾åα°Õ¤¹¤ë¤³¤È

¡¡¡Ê£±¡ËÎÑÍý¿³ºº°Ñ°÷²ñ¤Î¾µÇ§¤Ê¤É¤Ë¤Ä¤¤¤Æ ¡¡Î×¾²»î¸³¡¢Ì¤¾µÇ§Ìô¤Î»ÈÍÑÎ㤢¤ë¤¤¤ÏÆÃ¼ì¤Ê¸¡ºº¡¦¼£ÎÅÎã¤Ê¤É¿Í¤òÂоݤȤ·¤¿¸¦µæ¤Ï¡¢¡Ö¿Í¤òÂоݤȤ¹¤ë°å³Ø·Ï¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¡×¡ÊʸÉô²Ê³Ø¾Ê¡¢¸üÀ¸Ï«Æ¯¾Ê¡Ë¡ÊÊ¿À®26ǯ12·î22Æü¡¢Ê¿À®29ǯ2·î28Æü°ìÉô²þÀµ¡Ë¤Ë±è¤Ã¤Æ³Æ»ÜÀߤÎÎÑÍý°Ñ°÷²ñ¡¢¤Þ¤¿¤Ï³ºÅö¤¹¤ë¿³ººµ¡´Ø¤Ê¤É¤Î¾µÇ§¤òÆÀ¤¿¸å¤Ë´µ¼Ô¤ËÂФ¹¤ë¥¤¥ó¥Õ¥©¡¼¥à¥É¡¦¥³¥ó¥»¥ó¥È¤òʸ½ñ¤ÇÆÀ¤ëÅù¡¢ÎÑÍý»Ø¿Ë¤Ë±è¤Ã¤ÆÅ¬ÀÚ¤ËÆ±°Õ¤òÆÀ¤¿¤â¤Î¤Ç¤¢¤ë¤³¤È¡Ê´Ñ»¡¸¦µæ¤ä¸å¤í¸þ¤­¸¦µæÅù¤âÎÑÍý¿³ºº°Ñ°÷²ñ¤Ø¤Î¿½ÀÁ¤¬É¬Íסˡ£¤Þ¤¿¤½¤Î»Ý¡Ê¾µÇ§ÈÖ¹æ¤Ê¤É¡Ë¤òÏÀʸ¤ËÌÀµ­¤¹¤ë¡£¤µ¤é¤Ë¡¢2013 ǯ²þÄû¤Î¥Ø¥ë¥·¥ó¥­Àë¸À¤Ë§¤Ã¤Æ¼Â»Ü¤µ¤ì¤¿»Ý¤Îµ­ºÜ¤ò´Þ¤á¤ë¤³¤È¡£¤Ê¤ª½å¼é¤¹¤Ù¤­»Ø¿Ë¤Ï³Æ¾ÊÄ£¤Î³ºÅö¥µ¥¤¥È¤ò¤´Í÷¤¯¤À¤µ¤¤¡ÊÎ㡧ʸÉô²Ê³Ø¾Ê http://www.lifescience.mext.go.jp/bioethics/ekigaku.html¡Ë¡£
¡¡¤Ê¤ª¡¢3Îã°Ê²¼¤Î¾ÉÎãÊó¹ð¤ÏÎÑÍý°Ñ°÷²ñ¤Î¾µÇ§¤òɬ¿ÜÍ×·ï¤È¤·¤Ê¤¤¤¬¡¢³Æ»ÜÀߤε¬Ä꤬¤¢¤ì¤Ð¤½¤ì¤Ë½¾¤¦¤â¤Î¤È¤·¡¢¤«¤Ä´µ¼Ô¤â¤·¤¯¤ÏÂåÂú¼Ô¤«¤éƱ°Õ¤òÆÀ¤Æ¤ª¤¯¤³¤È¡£

¡¡¡Ê£²¡ËÎ×¾²»î¸³ÅÐÏ¿¤Ë´Ø¤¹¤ëÍ×·ï ¡¡Ãø¼Ô¤¬¼«¿È¤ÎÎ×¾²»î¸³¤òÅÐÏ¿µ¡´Ø¤ØÅÐÏ¿¤·¤¿¸¶¹Æ¤òÄó½Ð¤¹¤ë¾ì¹ç¤Ë¤Ï¡¢ÅÐÏ¿µ¡´Ø¤Ø¤ÎÅÐÏ¿IDÈÖ¹æ¤ò¾¶Ï¿¤ÎºÇ¸å¤Ëµ­Æþ¤¹¤ë¤³¤È¡£¸å¤í¸þ¤­»î¸³¤Î¾ì¹ç¡¢ÅÐÏ¿¤ÏÉÔÍפǤ¢¤ë¤¬¡¢¸å¤í¸þ¤­Ä´ºº¤«¤éÆÀ¤é¤ì¤¿·ë²Ì¤Ç¤¢¤ë¤³¤È¤ò¸¶¹Æ¤ÎºàÎÁ¤ÈÊýË¡¤Î¥»¥¯¥·¥ç¥ó¤Ëµ­Æþ¤¹¤ë¤³¤È¤ò¿ä¾©¤¹¤ë¡£

¡¡¡Ê£³¡Ë´µ¼Ô¾ðÊóÊݸî¤Ë¤Ä¤¤¤Æ Ê¿À®29ǯ5·î¤Ë»Ü¹Ô¤µ¤ì¤¿²þÀµ¸Ä¿Í¾ðÊóÊݸîË¡¤ò½å¼é¤·¡¢¾ÉÎãÊó¹ð¤Ê¤É¤Ë¤ª¤±¤ë´µ¼Ô¾ðÊó¤Î´Ø¤·¤Æ¤Ï¡¢°Ê²¼¤Î»Ø¿Ë¤ò½å¼é¤¹¤ë¤³¤È¡£

  • ´µ¼Ô¸Ä¿Í¤ÎÆÃÄ꤬²Äǽ¤Ê»á̾¡¢¥¤¥Ë¥·¥ã¥ë¡¢¥«¥ë¥ÆÈÖ¹æ¤Ê¤É¤Ïµ­ºÜ¤·¤Ê¤¤¡£
  • ǯÎðŽ¥À­Ê̤ϵ­ºÜ¤·¤Æ¤è¤¤¡£
  • ´µ¼Ô¤Î¸½½»½ê¤Ïµ­ºÜ¤·¤Ê¤¤¡£¤¿¤À¤·¡¢¼À´µ¤Îȯ¾É¾ì½ê¤¬ÏÀʸ¤Î¼ç»Ý¤Ë½ÅÍפʰյÁ¤¬¤¢¤ë¾ì¹ç¤Ë¸Â¤ê¡¢¶è°è¤Þ¤Ç¤Ïµ­ºÜ¤·¤Æ¤è¤¤¡ÊÎã¡§°¦Ãθ©¡¢Ì¾¸Å²°»Ô¡Ë
  • ÆüÉÕ¤Ïǯ·î¤Þ¤Ç¤È¤·¡¢Æü¤Ïµ­ºÜ¤·¤Ê¤¤¡£X+1ǯ¤Ê¤É¤Îɽµ­¤Î»ÈÍѤ⸡Ƥ¤¹¤ë¤³¤È¡£
  • ¤¹¤Ç¤Ë¾»ÜÀߤǿÇÎŤò¼õ¤±¤Æ¤¤¤ë¾ì¹ç¡¢¤½¤Î»ÜÀß̾¤ä½êºßÃϤϵ­ºÜ¤·¤Ê¤¤¡£
  • ÏÀʸ¤ÎºîÀ®¾å´µ¼Ô¼Ì¿¿¤òÄ󼨤¹¤ë¤³¤È¤¬ÉԲķç¤Ê¾ì¹ç¤Ë¸Â¤ê¡¢´µ¼Ô¤¬ÆÃÄê¤Ç¤­¤Ê¤¤¤è¤¦¤Ë½èÍý¤ò¤·¤¿¾å¤Ç»ÈÍѤ¹¤ë¡£(Î㤨¤Ð¡¢´éÌ̼̿¿¤Ç¤ÏÌܤò±£¤¹¡¢¤¢¤ë¤¤¤Ï³ºÅöÉôʬ¤ò³ÈÂç¼Ì¿¿¤È¤¹¤ë¤Ê¤É)
  • À¸¸¡¡¢Ë¶¸¡¡¢²èÁü¾ðÊó¡¢ÉÂÍýɸËܤʤɤòÄ󼨤¹¤ë¾ì¹ç¡¢´µ¼Ô¤òÆÃÄê¤Ç¤­¤ë¤è¤¦¤ÊÈÖ¹æ¤Ê¤É¤Î¾ðÊó¤Ïºï½ü¤¹¤ë¡£
  • ÏÀʸ¤ÎºîÀ®¾å´µ¼Ô¼Ì¿¿¤òÄ󼨤¹¤ë¤³¤È¤¬ÉԲķç¤Ê¾ì¹ç¤Ë¸Â¤ê¡¢´µ¼Ô¤¬ÆÃÄê¤Ç¤­¤Ê¤¤¤è¤¦¤Ë½èÍý¤ò¤·¤¿¾å¤Ç»ÈÍѤ¹¤ë¡£(Î㤨¤Ð¡¢´éÌ̼̿¿¤Ç¤ÏÌܤò±£¤¹¡¢¤¢¤ë¤¤¤Ï³ºÅöÉôʬ¤ò³ÈÂç¼Ì¿¿¤È¤¹¤ë¤Ê¤É)
  • °äÅÁÀ­¼À´µ¤ä¥Ò¥È¥²¥Î¥àŽ¥°äÅÁ»Ò²òÀϤò¤È¤â¤Ê¤¦Êó¹ð¤Ç¤Ï¡¢Ž¢¥Ò¥È¥²¥Î¥àŽ¥°äÅÁ»Ò²òÀϸ¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿ËŽ£(ʸÉô²Ê³Ø¾Ê¡¢¸üÀ¸Ï«Æ¯¾Ê¤ª¤è¤Ó·ÐºÑ»º¶È¾Ê)(Ê¿À®13ǯ3·î29Æü¡¢Ê¿À®29ǯ2·î28Æü°ìÉô²þÀµ)¤ò½å¼é¤¹¤ë¡£

¡¡¡Ê£´¡Ëµö²Ä ¡¡Â¾¤Ç¸ø³«ºÑ¤ß¤Î¿ÞɽËô¤ÏʸÌ̤ò´Þ¤á¤ë¾ì¹ç¡¢Ãø¼Ô¤Ï¼«¤é¤ÎÀÕǤ¤Ë¤ª¤¤¤ÆÃøºî¸¢ÊÝÍ­¼Ô¤«¤éµö²Ä¤òÆÀ¤Æ¡¢ÏÀʸ¤òÅê¹Æ¤¹¤ëºÝ¤ËÅö³ºµö²Ä¤¬ÆÀ¤é¤ì¤Æ¤¤¤ë»Ý¤Î¾Úµò¤òÅê¹Æ»þ¤ËÄó½Ð¤¹¤ë¡£¤«¤«¤ë¾Úµò¤Î¤Ê¤¤»ñÎÁ¤Ï¤¹¤Ù¤ÆÃø¼Ô¤Î¥ª¥ê¥¸¥Ê¥ë¤Ç¤¢¤ë¤È¤ß¤Ê¤µ¤ì¤ë¡£

£´¡Ë¸¶¹Æ¤ÎŤµ
¡¡¸¶¹ÆÊ¸»ú¿ô°ìÍ÷ɽ¤ò»²¾È¤¹¤ë¤³¤È¡£¤³¤Îµ¬Äêʸ»ú¿ô¤òĶ²á¤¹¤ë¤â¤Î¤Ï¡¢¸¶Â§¤È¤·¤Æ¼õ¤±ÉÕ¤±¤Ê¤¤¡£¤Ê¤ªÏÀʸÆâÍÆ¤ÎÍý²ò¤ÎÊä´°¤È¤Ê¤ë¤è¤¦¤ÊÊ䭥ǡ¼¥¿¤ÎÅê¹Æ¤òǧ¤á¤ë¡£ºÇ½é¤ÎÅê¹Æ»þ¤ËÆÈΩ¤·¤¿°ìÏ¢¤Î¸¶¹Æ¤È¤·¤ÆÄó½Ð¤¹¤ë¤³¤È¡£
  ËÜʸ¸¶¹ÆÊ¸»ú¿ô¢¨1
(±Ñʸ¸¶¹Æ¸ì¿ô)
ÏÂʸ¾¶Ï¿ ±Ñʸ¾¶Ï¿ ±Ñ¸ì¥­¡¼¥ï¡¼¥É
(5¸Ä¤Þ¤Ç)
ʸ¸¥¿ô ¿Þɽ¿ô
ÁíÀâ ÆÃ¤ËÀ©¸Â¤Ï¤·¤Ê¤¤ 400»ú 200¸ì ɬÍ× 50ÊÔ 6ÅÀ°ÊÆâ
¾·ÀÁÁíÀâ ÆÃ¤ËÀ©¸Â¤Ï¤·¤Ê¤¤ 400»ú 200¸ì ɬÍ× ÆÃ¤ËÀ©¸Â¤Ï¤·¤Ê¤¤ 10ÅÀ°ÊÆâ
¸¦µæÊó¹ð 5,400»ú
(3,500¸ì)
400»ú 200¸ì ɬÍ× 30ÊÔ 6ÅÀ°ÊÆâ
¾ÉÎãÊó¹ð 3,500»ú
(1,500¸ì)
400»ú 200¸ì ɬÍ× 15ÊÔ 4ÅÀ°ÊÆâ
ûÊó 2,000»ú
(1,500¸ì)
ÉÔÍ× 150¸ì ɬÍ× 10ÊÔ 2ÅÀ°ÊÆâ
³Ø²ñµ­ 2,000»ú
(1,500¸ì)
ÉÔÍ× 150¸ì ɬÍ× 15ÊÔ 2ÅÀ°ÊÆâ
»ä¤Î°ìËç¤Î²èÁü 500»ú ÉÔÍ× ÉÔÍ× ÉÔÍ× 3ÊÔ ¼Ì¿¿£±ÅÀ ¢¨2
³èưÊó¹ð 1,500»ú ÉÔÍ× ÉÔÍ× É¬Í× 15ÊÔ 4ÅÀ°ÊÆâ
¢¨1 ËÜʸ¸¶¹ÆÊ¸»ú¿ô¤Ëɽ»æ¡¢ÏÂʸ¾¶Ï¿¡¢±Ñʸ¾¶Ï¿¡¢Ê¸¸¥¡¢¿Þɽ¤Ï´Þ¤á¤Ê¤¤¡£
¢¨2 Ê£¿ô¤Î¼Ì¿¿¤ò1Ëç¤ÎÃæ¤ËÁȤ߹þ¤à¤³¤È¤Ï²Äǽ¤È¤¹¤ë¡£

£µ¡Ë¸¶¹Æ¤Î½ñ¤­Êý ¡¡É½»æ¡¢ÏÂʸ¾¶Ï¿¤ª¤è¤Ó±Ñʸ¾¶Ï¿¡¢½ï¸À¡¢ºàÎÁ¤ª¤è¤ÓÊýË¡¡¢·ë²Ì¡ÊÀ®ÀÓ¡Ë¡¢¹Í»¡¡¢¼Õ¼­¡¢Ãø¼ÔÌò³ä¡¢Íø±×ÁêÈ¿¤Î³«¼¨¡¢Ê¸¸¥¡¢É½¡¢¿Þ¡¦¼Ì¿¿¤ÎÀâÌÀ¡¢¿Þ¡¦¼Ì¿¿¤Î½çÈÖ¤Çʬ¤±¤Æ½ñ¤¯¤³¤È¡£
¡¡Ã»Êó¤Î¾ì¹ç¡¢½ï¸À¡¢ºàÎÁ¤ª¤è¤ÓÊýË¡¡¢·ë²Ì¡ÊÀ®ÀÓ¡Ë¡¢¹Í»¡¤ò°ì³ç¤·¤Æµ­ºÜ¤·¤Æ¤â¤è¤¤¤¬¡¢ÃÊÍî¤Ëʬ¤±¤ë¤Ê¤ÉÆÉ¤ß¤ä¤¹¤¤¤è¤¦¤ËÅØ¤á¤ë¤³¤È¡£¤½¤ì°Ê³°¤Î¹àÌܤÏɬ¿Ü¤Ç¤¢¤ë¡£
¡¡¡Ö³èưÊó¹ð¡×¤Ïʸ¾¶Ï¿¤ª¤è¤Ó±Ñʸ¾¶Ï¿¤ÏÉÔÍפǤ¢¤ë¤¬¡¢¤½¤ì°Ê³°¤Ë¤Ä¤¤¤Æ¤Ï¸¦µæÊó¹ð¤Ë½à¤º¤ë¤³¤È¤¬Ë¾¤Þ¤·¤¤¡£¡Ö»ä¤Î°ìËç¤Î²èÁü¡×¤Îµ­ºÜÊýË¡¤Ë¤ÏÆÃ¤ËÀ©Ìó¤Ï¤Ê¤¤¤¬¡¢³Ø½ÑÍѸ졢ÌôÉÊ̾¡¢Ê¸¸¥¤Ï¸¦µæÊó¹ð¤Ë½à¤º¤ë¤³¤È¡£

¡¡¡Ê£±¡Ëɽ»æ ¡¡¾åÃʤ˸¶¹Æ¤Î¼ïÎà¤ò¡¢ÃæÃʤËÏÀʸɽÂê¡¢Ãø¼Ô̾¡¢½ê°»ÜÀߤʤé¤Ó¤Ë¤³¤ì¤é¤Î±ÑÌõ¤Î½ç¤Ëµ­¤·¡¢²¼ÃʤËÏ¢ÍíÀè¡Êcorresponding author̾¡¢½»½ê¡¢ÅÅÏá¢FAX¡¢¥á¡¼¥ë¥¢¥É¥ì¥¹¡Ë¤òÌÀµ­¤¹¤ë¡£

¡¡¡Ê£²¡ËɽÂê ¡¡ÏÂʸɽÂê¤Ï50»ú°ÊÆâ¡¢±ÑʸɽÂê¤Ï25¸ì°ÊÆâ¤È¤¹¤ë¡£É½Âê¤Ë¤ÏÌôÉʤξ¦ÉÊ̾¤òµ­ºÜ¤·¤Ê¤¤¡£¤¿¤À¤·ÏÀʸ¤ÎÆâÍÆ¤«¤éɬÍפȹͤ¨¤é¤ì¤ë»þ¤Ï¡¦¡¦¡¦®¤Èɽµ­¤¹¤ë¡£¤Þ¤¿¡¢É½Âê¤Ë¤Ïά¸ì¤ò»ÈÍѤ·¤Ê¤¤¡£¤Þ¤¿¡¢¸«½Ð¤·ÍѤÎû¤¤É½Âê¤òÆüËܸì¤Ç¤¢¤ì¤Ð20»ú°ÊÆâ¡¢±Ñ¸ì¤Ç¤¢¤ì¤Ð50ʸ»ú°ÊÆâ¤òµ­ºÜ¤¹¤ë¤³¤È¡£

¡¡¡Ê£³¡Ë¾¶Ï¿ ¡¡ÏÂʸ¾¶Ï¿¤Ï¡¢ÁíÀâ¡¢Î×¾²¸¦µæµÚ¤Ó¾ÉÎãÊó¹ð¤Ë¤Ä¤¤¤Æ¤Ï400»ú°ÊÆâ¡¢Ã»Êó¤Ë¤Ä¤¤¤Æ¤ÏÉÔÍפȤ¹¤ë¡£±Ñʸ¤Ç¤ÎÅê¹Æ¤Î¾ì¹ç¤Ï¡¢ÆüËܸ쾶Ͽ¤ÏÉÔÍפȤ¹¤ë¡£±Ñʸ¾¶Ï¿¤Ï¡¢ÁíÀâ¡¢Î×¾²¸¦µæ¤Ë¤Ä¤¤¤Æ¤Ï200¸ì°ÊÆâ¡¢Ã»Êó¤Ï150¸ì°ÊÆâ¤È¤·¡¢±Ñ¸ì¤ÎKey words¡Ê5¸Ä°ÊÆâ¡Ë¤òÉÕ¤±¤ë¡£

¡¡¡Ê£´¡ËËÜʸ ¡¡A4¥µ¥¤¥º¤Ç²£½ñ¤­¡¢¥Õ¥©¥ó¥È¥µ¥¤¥º12¥Ý¥¤¥ó¥È¤Ç°õ»ú¤¹¤ë¡£Ìܰ¤Ȥ·¤ÆÏÂʸÏÀʸ¤Î¾ì¹ç¤Ï¡¢1¥Ú¡¼¥¸35»ú¡ß21¹Ô¤È¤¹¤ë¡£¤Þ¤¿É½Âê¤òÂè1¥Ú¡¼¥¸¤È¤·¤Æ¡¢¥Õ¥Ã¥¿¡¼Ãæ±û¤Ë¥Ú¡¼¥¸ÈÖ¹æ¤òµ­ºÜ¤¹¤ë¡£
¡¡³Ø½ÑÍѸì¤Ï¡ÖÆüËܰ峨²ñ°å³ØÍѸ켭ŵ¡×¤ÎºÇ¿·ÈǤ˽àµò¤¹¤ë¡£¿Í̾¤Ï¸¶¸ì¤òÍѤ¤¤ë¡£
¡¡ÌôÉʤòµ­ºÜ¤¹¤ë¾ì¹ç¡¢¾¦ÉÊ̾¤ÏƬʸ»ú¤òÂçʸ»ú¡¢¤Þ¤¿²½³ØÌ¾¤ä°ìÈÌ̾¤ÏƬʸ»ú¤ò¾®Ê¸»ú¤Çɽµ­¤¹¤ë¡£
¡¡ÅÙÎ̹դÎñ°Ì¤Ï
¡¡①½Å¤µ¤Ë´Ø¤·¤Æ¡§t, kg, g, mg, ¦Ìg, ng, pg¤Ê¤É
¡¡②Ťµ¤Ë´Ø¤·¤Æ¡§m, cm, mm, ¦Ìm, nm¤Ê¤É
¡¡③ÍÆÀѤ˴ؤ·¤Æ¡§l, dl, ml, ¦Ìl, nl, pl, fl¤Ê¤É
¡¡④Ç»Å٤˴ؤ·¤Æ¡§g/l, ­Ó/l, mol/l, g/dl¤Ê¤É
¡¡⑤Êü¼ÍÀþÅù¤Îñ°Ì¤Ë´Ø¤·¤Æ¡§Gy, Bq, C/kg, Sv¤Ê¤É
¡¡¤òÍѤ¤¤ë¡£

¡¡¡Ê£µ¡Ëά¸ì ¥¿¥¤¥È¥ë¤Ë¤Ï¸¶Â§¤È¤·¤ÆÎ¬¸ì¤ò»ÈÍѤ·¤Ê¤¤¡£ËÜÊ¸Ãæ¤Ëά¸ì¤ò»ÈÍѤ¹¤ë¾ì¹ç¤Ï¡¢½é½Ð²Õ½ê¤Ë¡¢¡Ö¥Õ¥ë¥Í¡¼¥à¡Êά¸ì¡Ë¡×¤Î·Á¼°¤Çµ­ºÜ¤¹¤ë¡£
¡ÎÎã¡Ï±Ñʸµ­ºÜ»þ¡§graft versus host disease (GVHD)
¡ÎÎã¡ÏÆüËܸ쵭ºÜ»þ¡§¹³¶»Á£ºÙ˦¥°¥í¥Ö¥ê¥ó¡Êantithymocyte globulin¡¤ATG¡Ë

¡¡¡Ê£¶¡Ë¼Õ¼­¡¢Ãø¼ÔÌò³ä¡¢Íø±×ÁêÈ¿¤Î³«¼¨ ¼Õ¼­¤Ë¤Ï¸¦µæ¤Î¿ë¹Ô¤òÊä½õ¤·¤¿¸¦µæÈñ¤Î½Ð½è¡¢¸Ä¿Í¡¢¤¢¤ë¤¤¤ÏÃÄÂÎ̾¤òµ­ºÜ¤¹¤ë¡£Ãø¼ÔÌò³ä¡ÊAuthors' contributions¡Ë¤Ë¤Ï¡¢Ìò³äÊ̤˴ØÍ¿¤·¤¿Ãø¼Ô¤Î¥¤¥Ë¥·¥ã¥ëÅù¤ò´Ê·é¤Ëµ­ºÜ¤¹¤ë¡£Íø±×ÁêÈ¿¤Ë¤Ä¤¤¤Æ¤ÏÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ¤ÎÍø±×ÁêÈ¿»Ø¿Ë¡¦ºÙ§¤Ë½à¤¸¡¢Ãø¼ÔÁ´°÷¤Ë¤Ä¤¤¤ÆÍø±×ÁêÈ¿¤Î¾õÂÖ¤Î̵ͭ¤ò³«¼¨¤¹¤ë¡£Corresponding author¡ÊÏ¢ÍíÃø¼Ô¡Ë¤ÏÃø¼ÔÁ´°÷¤ÎÍø±×ÁêÈ¿´ÉÍý¤Ë¤Ä¤¤¤ÆÀÕǤ¤ò»ý¤Ä¤³¤È¡£Íø±×ÁêÈ¿¤¬¤¢¤ë¾ì¹ç¤Ï¡¢¡ÖÍø±×ÁêÈ¿¡ÊCOI¡Ë»Ø¿Ë¡¦ºÙ§¡¦µ¬Äø¡¢µÚ¤Ó¿½¹ð½ñ¡×¡Êhttp://www.jshct.com/organization/about_riekisouhan.shtml¡Ë¤Î¡ÖÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ»¨»ï¡§¼«¸Ê¿½¹ð¤Ë¤è¤ëCOIÊó¹ð½ñÍͼ°¡×¤Ëµ­ºÜ¤·¥ª¥ó¥é¥¤¥óÅê¹Æ¥·¥¹¥Æ¥à¤Ç¥¢¥Ã¥×¥í¡¼¥É¤¹¤ë¤«¡¢ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ»ö̳¶ÉÊÔ½¸°Ñ°÷²ñ¤ØFAX¤ÇÁ÷¿®¤¹¤ë¤³¤È¡£

Íø±×ÁêÈ¿³«¼¨¤Îµ­ºÜÎã¡§
¡Ê1¡ËÍø±×ÁêÈ¿¤Î¤Ê¤¤¾ì¹ç¡§
ÆüËܸìÏÀʸ¡§Ãø¼Ô¤ÎÍø±×ÁêÈ¿³«¼¨¡§ËÜÏÀʸȯɽÆâÍÆ¤Ë´ØÏ¢¤·¤ÆÆÃ¤Ë¿½¹ð¤Ê¤·¡£
±Ñ¸ìÏÀʸ¡§The authors declare no conflict of interest.
¡Ê2¡ËÍø±×ÁêÈ¿¤Î¤¢¤ë¾ì¹ç
Ãø¼Ô¤ÎÍø±×ÁêÈ¿¤Ï²¼µ­¤Ë¼¨¤¹Ä̤ê¤Ç¤¢¤ë¡£
Ãø¼Ô̾¤´¤È¤ËÏÀʸȯɽÆâÍÆ¤Ë´ØÏ¢¤·Íø±×ÁêÈ¿¾õÂ֡ʹàÌܤ´¤È¤Ë´ð½à³Û¤òͤ¨¤Æ¤¤¤ë¾ì¹ç¡Ë¤Ë¤¢¤ë´ë¶È¡¦ÁÈ¿¥¤Þ¤¿¤ÏÃÄÂÎ̾¤òµ­ºÜ¤¹¤ë¡£
¹àÌÜ¡§Êó½·¡¤³ô¼°Íø±×¡¤ÆÃµö»ÈÍÑÎÁ¡¤¹Ö±éÎÁ¡¤¸¶¹ÆÎÁ¡¤¸¦µæÈñ¡¦½õÀ®¶â¡¤´óÉն⡤´óÉչֺ¡¤Î¹Èñ¡¦Â£ÅúÉʤνçÈ֤ˤƵ­ºÜ¤¹¤ë¡£
¡¡¡¦µ­ºÜÎã¡§
ÆüËܸìÏÀʸ¡§Ãø¼Ô¤ÎÍø±×ÁêÈ¿¤Î³«¼¨¡§ÆüËֻܲҡ¨
¹Ö±éÎÁ¡ÊAAÀ½Ìô¡Ë¡¤´óÉÕ¶â¡ÊBBÀ½Ìô¡Ë¡¤¹Ö±éÎÁ¡ÊË̳¤Æ»À½Ìô¡Ë¡¤¸¦µæÈñ¡¦½õÀ®¶â¡ÊCCÀ½Ìô¡Ë¡¤´óÉչֺ¡ÊDDÀ½Ìô¡Ë

¡¡¡Ê£·¡Ëʸ¸¥ ËÜʸ¤Ë°úÍѤ·¤¿½çÈÖ¤ËÈÖ¹æ¤òÉÕ¤±ÇÛÎ󤹤롣¤Ê¤ªËÜÊ¸Ãæ¤Ç¤Ï¾åÉÕʸ»ú¤Çʸ¸¥ÈÖ¹æ¤òÉÕ¤¹¤³¤È¡£ÏÂʸ»ï̾¤Îά¹æ¤Ï°å³ØÃæ±û»¨»ï¼ýºÜ»ïÌÜϿά̾ɽ¤ò»ÈÍѤ·¡¢³°¹ñ¤Îʸ¸¥¤ÏIndex Medicus½êºÜ¤Î¤â¤Î¤Ë½à¤º¤ë¡£

  • ①¸¶Ãø¤Î¾ì¹ç¡§Ãø¼Ô̾. ÏÀʸÂê̾. »¨»ï̾. À¾Îñ¡¨´¬¡§ÊÇ-ÊÇ.
    ¡Ê¶¦Ãø¼Ô¤¬5̾¤Þ¤Ç¤Ï¤¹¤Ù¤Æ¤Î̾Á°¤òµ­¤¹¡£6̾°Ê¾å¤Î¾ì¹ç¤ÏɮƬ¼Ô¤«¤é3¿ÍÌܤޤǤòµ­¤·¡¢4¿ÍÌܤ«¤é¤Ï¾Êά¤·¤Æ"¤Û¤«"¡¢±Ñʸ¤Î¾ì¹ç"et al."¤È¤¹¤ë¡£¡Ë
    1. ¡ÎÎã¡Ï
    2. 1.Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010; 115: 1343-1350.
    3. 2.Ç븶ÕòÂÀϺ¡¤Ë¾·îÊþÈþ¡¤¶áÆ£Èþµª¡¤¤Û¤«¡¥²æ¤¬¹ñ¤Ë¤ª¤±¤ëƱ¼ï¤·ì´´ºÙ˦°Ü¿¢´µ¼Ô¤ÎĹ´ü¥Õ¥©¥í¡¼¥¢¥Ã¥×¤Î¼ÂÂÖÄ´ºº¡¥Î×¾²·ì±Õ¡¥2010¡¨ 51¡§167-173.
    4. 3.Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant. 2004; 33: 1187-1190.

  • ②³Ø²ñ¾¶Ï¿¤Î¾ì¹ç¡§Ãø¼Ô̾. ¾¶Ï¿Âê̾¡Î¾¶Ï¿¡Ï. »¨»ï̾. À¾Îñ¡¨´¬ ¡§ÊÇ. ¾¶Ï¿ÈÖ¹æ.
    1. 4.²ÖÅÄÎɯ󡤵ÆÃÓÍÛ¡¤¹¯¾¡¹¥¡¤¤Û¤«¡¥Â¤·ì´ï¼À´µ´µ¼Ô¤ÎË㿾¹³ÂβÁ¡Î¾¶Ï¿¡Ï¡¥Æü¾®·ì²ñ»ï¡¥2002¡¨16¡§246. 112.
    2. 5.Palumbo A, Cavallo F, Hardan I, et al. Melphalan/prednisone/ lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65 years: results of a randomized phase III study. ¡Îabstract¡Ï Blood. 2011; 118: 3069.

  • ③Ãø½ñ¤Î¾ì¹ç¡§Ãø¼Ô̾. Âê̾. ´Æ½¤¼Ô̾¡ÊÊÔ¼Ô̾¡Ë. ½ñ̾. ÈÇ. ȯ¹ÔÃÏ, ȯ¹Ô½ê¡¨À¾Îñǯ¹æ¡¨ÊÇ-ÊÇ
    1. 6.¡¡Ì¾ÏÂͳ°ìϺ¡¤ÌÚ¸ýÂçÊå¡¥GVHD´µ¼Ô¤Î¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¡¥¤ß¤ó¤Ê¤ËÌòΩ¤ÄGVHD¡Ê°Ü¿¢ÊÒÂнɼçÉ¡ˤδðÁäÈÎ×¾²¡¥Ë­Åè¿òÆÁ¡ÊÊÔ½¸¡Ë¡¥Âçºå¡¤°åÌô¥¸¥ã¡¼¥Ê¥ë¼Ò¡¥2013¡§411-419.

  • ④¥ª¥ó¥é¥¤¥ó»ñÎÁ¤Î¾ì¹ç¡§Ãø¼Ô̾¡ÊÊÔ¼Ô̾¡Ë¡§¥µ¥¤¥È̾(URL). ºÇ½ª¥¢¥¯¥»¥¹Æü.
    ¢¨(Digital Object Identifier (DOI) ¤¬ÉÕÍ¿¤µ¤ì¤Æ¤¤¤ë¾ì¹ç¤ÏDOI¤òµ­Æþ¤¹¤ë¤³¤È¡£
    1. 7.ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ¡¥Â¤·ìºÙ˦°Ü¿¢¥¬¥¤¥É¥é¥¤¥ó¡¡Í½ËÉÀܼ
      (http://www.jshct.com/guideline/pdf/2008yobousesshu.pdf) Accessed 2014 March 31.

¡¡¡Ê£¸¡Ë¿Þɽ ¿Þ¡Ê¼Ì¿¿¤ò´Þ¤à¡Ë¤ª¤è¤Óɽ¤Ï°úÍѽç¤Ë¤½¤ì¤¾¤ìÈÖ¹æ¤òÉÕ¤±¡¢ÁÞÆþ²Õ½ê¤ÏËÜÊ¸Ãæ¤ËÌÀµ­¤¹¤ë¡£É½Âꤪ¤è¤ÓÀâÌÀ¤Ï²Äǽ¤Ê¸Â¤ê±Ñʸ¤Çµ­ºÜ¤·¡¢¿ÞÉ½Ãæ¤Îʸ»ú¤â¤½¤ì¤Ë½à¤¸±Ñ¸ì¤Çɽµ­¤¹¤ë¡£¿Þ¤ÎÀâÌÀ¡ÊLegend¡Ë¤Ë¤Ïɬ¤º¥¿¥¤¥È¥ë¤òÉÕ¤±¤Æ²¼¤µ¤¤¡£¤Þ¤¿¿Þ¤ä¼Ì¿¿¤Ï¤½¤Î¤Þ¤ÞÁÈÈǤËÍѤ¤¤é¤ì¤ë¤¿¤á³ÈÂ礷¤Æ¤â½½Ê¬Á¯ÌÀ¤Ê¤â¤Î¤È¤·¡¢¥Ç¥¸¥¿¥ë¥Ç¡¼¥¿²½¤·¤Æ¤«¤é¥¢¥Ã¥×¥í¡¼¥É¤¹¤ë¤³¤È¡£É½¤Ï²èÁü¤Ç¤Ï¤Ê¤¯Ê¸»ú¤òÃê½Ð¤Ç¤­¤ë·Á¼°¡Ê¥ï¡¼¥É¥×¥í¥»¥Ã¥µ¡¢¥¹¥×¥ì¥Ã¥É¥·¡¼¥È¤Ê¤É¡Ë¤ÇÄó½Ð¤¹¤ë¤«¡¢ÏÀʸ¥Õ¥¡¥¤¥ë¤ÎËöÈø¤ËÁÞÆþ¤¹¤ë¤³¤È¡£¤Þ¤¿Â¾¤Î½ÐÈÇʪ¤Ç·ÇºÜ¤µ¤ì¤Æ¤¤¤ë¿Þɽ¤òžºÜ»ÈÍѤ¹¤ë¾ì¹ç¤Ï¡¤Ãø¼ÔÀÕǤ¤Ë¤ª¤¤¤ÆÅê¹ÆÁ°¤ËÃøºî¸¢¼Ô¤ÎžºÜµöÂú¤òÆÀ¤Æ¤«¤éÅê¹Æ¤¹¤ë¤³¤È¡£

¡¡¡Ê£¹¡Ë±Ñʸ¹»Àµ ±Ñʸ¡ÊÏÂʸÏÀʸ¤Î¾¶Ï¿¤ò´Þ¤à¡Ë¤Ïnative speaker¤Ë¤è¤ë±Ñʸ¹»Àµ¤òºÑ¤Þ¤»¤Æ¤«¤éÅê¹Æ¤·¡¢¤½¤Î¾ÚÌÀ¤È¤Ê¤ë¤â¤Î¤ò¥ª¥ó¥é¥¤¥óÅê¹Æ¥·¥¹¥Æ¥à¤Ç¥¢¥Ã¥×¥í¡¼¥É¤¹¤ë¤³¤È¡£Åê¹Æ¤µ¤ì¤¿ÏÀʸ¤Î±Ñʸ¤Ë´Ö°ã¤¤¤¬Â¿¤¤¾ì¹ç¤Ë¤Ï¡¢ººÆÉÁ°¤ËÊÖÁ÷¤¹¤ë¾ì¹ç¤¬¤¢¤ë¡£ºÆÅê¹Æ»þ¤Î±Ñʸ¹»Àµ¤ÏÌȽü¤µ¤ì¤ë¤¬¡¢¼õÍý¤µ¤ì¤¿»þÅÀ¤Ç±Ñ¸ì¤ËÌäÂ꤬¤¢¤ë¤ÈȽÃǤµ¤ì¤¿¾ì¹ç¤Ï±Ñʸ¹»Àµ¤òµá¤á¤é¤ì¤ë¤³¤È¤¬¤¢¤ë¡£¤Ê¤ªÂÅÅö¤ÊÊýË¡¤¬¸«¤Ä¤«¤é¤Ê¤¤¾ì¹ç¤ÏÊÔ½¸°Ñ°÷²ñ¤Ç±Ñʸ¹»Àµ¡ÊÍ­ÎÁ¡¤¼ÂÈñ¡Ë¤ò°ÍÍꤹ¤ë¤³¤È¤â¤Ç¤­¤ë¡£

¡¡¡Ê£±£°¡ËÊä½õ¥Ç¡¼¥¿ ÏÀʸËÜÂΤˤϷǺܤ·¤Ê¤¤¤¬¡¢ÏÀʸ¤ÎÆâÍÆ¤òÊä´°¤¹¤ë¤Î¤ËɬÍפÊÊýË¡ÏÀ¤ÎÀâÌÀ¤ä¡¢À¸¥Ç¡¼¥¿¡Ê¥¢¥ó¥±¡¼¥ÈÅù¡Ë¡¢¿ÞɽÅù¤òÊÌÅÓ¡Ö´ØÏ¢¥Ç¡¼¥¿¡×¡¦¡ÖÊä½õ»ñÎÁ¡×¤È¤·¤Æ¥¢¥Ã¥×¥í¡¼¥É¤·¤Æ¤âÎɤ¤¡£

¡¡¡Ê£±£±¡Ë¥«¥Ð¡¼¥ì¥¿¡¼¤ª¤è¤ÓººÆÉ¼Ô¤Ø¤Î²óÅú ½é²óÅê¹Æ¡¦ºÆÅê¹Æ»þ¤Ë¤Ï¥«¥Ð¡¼¥ì¥¿¡¼¤òºîÀ®¤·¥¢¥Ã¥×¥í¡¼¥É¤·¤Æ²¼¤µ¤¤¡£¤Þ¤¿Åê¹Æ»þ¤Ë¿äÁ¦¤·¤¿¤¤ººÆÉ¼Ô¸õÊä¤Þ¤¿¤ÏººÆÉ°ÍÍê¤ò´õ˾¤·¤Ê¤¤¸õÊä¤òµ­ºÜ¤¹¤ë¤³¤È¤¬½ÐÍè¤Þ¤¹¡£ºÆÅê¹Æ»þ¤Ë¤ÏººÆÉ°Õ¸«¤ËÂФ¹¤ë²óÅú¤ò¥«¥Ð¡¼¥ì¥¿¡¼¤Ë°ú¤­Â³¤­µ­ºÜ¤·¤Æ²¼¤µ¤¤¡£

¡¡¡Ê£±£²¡Ë¼õÉÕÆü¡¦¼õÍýÆü ¥ª¥ó¥é¥¤¥óÅê¹Æ»þ¤ÏɬÍ×»ö¹à¤¬Á´¤ÆÀ°¤Ã¤Æ¤¤¤ë¤³¤È¤¬³Îǧ½ÐÍ褿»þÅÀ¤ÇÅê¹Æ¤Ï´°Î»¤¹¤ë¤¬¡¢¶¦Ãø¼Ô¤ËÁ÷¤é¤ì¤¿¥á¡¼¥ë¤Ç¶¦Ãø¼ÔÁ´°÷¤¬Åê¹Æ¤ò¾µÇ§¤·¤¿Æü¤ò¼õÉÕÆü¡¢ººÆÉ¤ò·Ð¤ÆºÎÂò¤È·èÄꤷ¤¿Æü¤ò¼õÍýÆü¤È¤¹¤ë¡£

£´¡¥ÏÀʸ¤ÎºÎÈÝ

Åê¹Æ¤µ¤ì¤¿ÏÀʸ¤Î¿³ºº¤Ï¡¢Editor-in-Chief ¤¬Ç¤Ì¿¤·¤¿Associate Editor 1̾¡¢Editorial Board ¤ò´Þ¤àººÆÉ¼Ô2¡Á3̾¡ÊÈ󳨲ñ°÷¤â²Ä¡Ë¤Ë¤è¤ê¹Ô¤ï¤ì¡¢Ã´Åö¤·¤¿Associate Editor¤¬È½Äê°Õ¸«Ä󼨤ò¹Ô¤¤¡¢ºÇ½ªÈ½Äê¤ÏEditor-in-Chief¤¬·èÄꤹ¤ë¡£Ã´Åö¤·¤¿Associate Editor̾¤ÏÏÀʸ½ñ»ï¾ðÊó¤Ëµ­ºÜ¤µ¤ì¤ë¡£
¾·ÀÁÁíÀâ¤Î¾ì¹ç¤ÏEditor-in-Chief¤ª¤è¤ÓEditor-in-Chief ¤¬Ç¤Ì¿¤·¤¿Associate Editor 2̾¤¬¿³ºº¤ò¹Ô¤¤¡¢Editor-in-Chief ¤¬ººÆÉ°Õ¸«¤òÄÌÃΤ¹¤ë¡£¤Ê¤ª¡¢ººÆÉ²áÄø¤Þ¤¿¤ÏÊÔ½¸²áÄø¤Ç¡¢¿Þɽ¤ò´Þ¤á·Á¼°¡¦ÇÛÃÖÅù¤Î½¤Àµ¤ò°ÍÍꤹ¤ë¤³¤È¤¬¤¢¤ë¡£
¿³ºº¤Î·ë²Ì¡¢½¤Àµ¤òµá¤á¤é¤ì¤¿¾ì¹ç¤Ï¡¢Åê¹Æ¼Ô¤Ï¡¢ÏÀʸ¿³ºº°Ñ°÷²ñ¤ÎººÆÉ°Õ¸«¤Ë½¾¤¤½¤Àµ¤Î¾å¡¢90Æü°ÊÆâ¤ËºÆÅê¹Æ¤Ç¤­¤ë¡£¤³¤ÎºÝ¡¢³ÆººÆÉ°Õ¸«¤ËÂФ·¤Æ²óÅú¤òµ­ºÜ¤·¤¿¼ê»æ¤òźÉÕ¤¹¤ë¤È¤È¤â¤Ë¡¢ºÆÅê¹ÆÏÀʸÆâ¤Î½¤ÀµÅÀ¤ò²¼Àþ¤äÀÖ»ú¤Ê¤É¤ÇÌÀ¼¨¤¹¤ë¤³¤È¡£ºÆÅê¹Æ¤µ¤ì¤¿ÏÀʸ¤Ë¤Ä¤¤¤Æ¤Ï¡¢½é²óÅê¹Æ»þ¤ÈƱÍͤ˿³ºº¤·¡¢ºÎÈݤò·èÄꤹ¤ë¡£

£µ¡¥ºÎÈÝÄÌÃÎ

¿³ºº·ë²Ì¤Ï¥ª¥ó¥é¥¤¥ó¥·¥¹¥Æ¥à¤«¤é¥á¡¼¥ë¤ÇÏ¢Íí¤µ¤ì¤ë¡£ÁÈÈǤˤ¢¤¿¤ê¡¢¿Þ¤Ë¤Ä¤¤¤Æ¤ÏÅê¹Æ»þ¤Î¤â¤Î¤ò¸¶Â§»ÈÍѤ¹¤ë¤¬¡¢²è¼Á¤¬ÉÔ½½Ê¬¤Î¾ì¹ç¤ÏºÆÄó½Ð¤òµá¤á¤ë¤³¤È¤¬¤¢¤ë¡£

£¶¡¥ÁÈÈǤª¤è¤ÓÃø¼Ô¹»Àµ

ËÜ»ï¤ÎÊÔ½¸Êý¿Ë¤ä¥¹¥¿¥¤¥ë¤ÎÅý°ìÀ­¤òÊݤĤ¿¤á¤ËÍѸì¤ä½ñ¼°¤ò½¤Àµ¤¹¤ë¤³¤È¤¬¤¢¤ë¡£Ãø¼Ô¹»Àµ¤Ï¸¶Â§¤È¤·¤Æ½é¹»¤Î¤ß¤È¤·¡¢48»þ´Ö°ÊÆâ¤ËÊֵѤ¹¤ë¡£¹»Àµ¤Ïæ»ú¡¢¸í¿¢ÄûÀµ¤Ë»ß¤á¡¢¸¶Ê¸¤ÎÊѹ¹¡¢ºï½ü¡¢ÁÞÆþ¤Ïǧ¤á¤Ê¤¤¡£

£·¡¥·ÇºÜÎÁ

·ÇºÜ¤µ¤ì¤¿ÏÀʸ¤Î1¥Ú¡¼¥¸¤¢¤¿¤ê3,500±ß¤òÃø¼ÔÉéô¤È¤·¡¢È¯¹Ô¤µ¤ì¤¿»þÅÀ¤ÇÀÁµá½ñ¤¬Á÷ÉÕ¤µ¤ì¤ë¡£¤Þ¤¿¡¢ÊÔ½¸°Ñ°÷²ñ¤Ç±Ñʸ¹»Àµ¤ò¹Ô¤Ã¤¿¾ì¹ç¡¢¹»ÀµÈñÍÑ¤âÆ±»þ¤ËÀÁµá¤µ¤ì¤ë¡£ ¤µ¤é¤ËÁá´ü¸ø³«¤ò´õ˾¤¹¤ë¾ì¹ç¤ÏÊÌÅÓ20,000±ß¤¬É¬ÍפǤ¢¤ë¡£¤Ê¤ª¾·ÀÁÁíÀâ¤Ë¤Ä¤¤¤Æ¤ÏÃø¼ÔÉéô¤Ï¤Ê¤¤¡£

£¸¡¥Ãøºî¸¢

ËÜ»ï¤Ë·ÇºÜ¤µ¤ì¤¿ÏÀʸ¤ÎÃøºî¸¢¤Ï¡¢ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ¤Ëµ¢Â°¤¹¤ë¡£¤Þ¤¿ËÜ»ï·ÇºÜÏÀʸ¤ÏJ-STAGE¤Ç¥ª¥ó¥é¥¤¥ó¸ø³«¤µ¤ì¤ë¡£¤Ê¤ª¡¢Ãøºî¸¢¤ÏÊ£¼ÌÅù¤Ë¤è¤êºÆÀ¸¤¹¤ëÊ£À½¸¢¡¢FAX¡¢¥¤¥ó¥¿¡¼¥Í¥Ã¥È¤Ê¤É¤ÇÆâÍÆ¤òÁ÷¿®¤¹¤ë¸ø½°Á÷¿®¸¢¡¢ËÝÌõ¸¢¡¢Æó¼¡ÅªÃøºîʪ¤ÎÍøÍѤ˴ؤ¹¤ë¸¢Íø¤Ê¤É¤ò»Ø¤¹¡£

£¹¡¥È³Â§µ¬Äê

Æó½ÅÅê¹Æ¡¢ÅðÍÑ¡¢ÙÔ¤¡¢Íø±×ÁêÈ¿¤Î³«¼¨¤Ë°ãÈ¿¤¬Ç§¤á¤é¤ì¤¿¾ì¹ç¡¢¿³ººÃæ¤Ç¤¢¤ì¤ÐÏÀʸ¤òµÑ²¼¤¹¤ë¡£·ÇºÜ¸å¤Î¾ì¹ç¤Ï¡¢ÏÀʸ¤òű²ó¤¹¤ë»Ý¤ò¥ª¥ó¥é¥¤¥ó¤Ç¸ø³«¤¹¤ë¡£¤µ¤é¤ËÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñÎÑÍý¿³ºº°Ñ°÷²ñ¤ª¤è¤ÓÍø±×ÁêÈ¿°Ñ°÷²ñ¤¬Èó¾ï¤Ë°­¼Á¤ÈȽÃǤ·¤¿¾ì¹ç¤Ë¤Ï¡¢Íý»ö²ñ¿³ºº¤ò·Ð¤Æ½èʬ¤ò·èÄꤹ¤ë¡£

£±£°¡¥Ï¢ÍíÀè

¢©461-0047
°¦Ãθ©Ì¾¸Å²°»ÔÅì¶èÂ繬Æî1ÃúÌÜ1-20
̾¸Å²°Âç³Ø°å³ØÉôÆâ
°ìÈ̼ÒÃÄË¡¿Í¡¡ÆüËܤ·ìºÙ˦°Ü¿¢³Ø²ñ»ö̳¶É¡¡ÊÔ½¸°Ñ°÷²ñ
TEL:052-719-1824
FAX:052-719-1828
E-mail¡§